FDA pharmacologic class
Alkylating Drug
16 medicines are in FDA's class of alkylating drugs: cyclophosphamide (Frindovyx), temozolomide (Temodar), mitomycin (Zusduri), bendamustine (Vivimusta), melphalan (Hepzato), thiotepa (Tepadina), carmustine (Gliadel), lomustine (Gleostine) and 8 more. 11 of the 16 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is temozolomide 20 mg capsule at $0.880 per capsule (NADAC).
Which medicines are alkylating drug?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Cyclophosphamide | Frindovyx | 19 labelers | $1.67 per capsule 50 mg capsule | No | No current entry | 6 |
| Temozolomide | Temodar | 11 labelers | $0.880 per capsule 20 mg capsule | No | No current entry | 18 |
| Mitomycin | Zusduri, Jelmyto, Mitosol | 11 labelers | n/a | Yes | No current entry | 2 |
| Bendamustine | Treanda, Vivimusta, Gobarden | 4 labelers | n/a | No | A presentation being discontinued | 1 |
| Melphalan | Hepzato, Evomela, Ivra | 13 labelers | n/a | Yes | A presentation being discontinued | 0 |
| Thiotepa | Tepadina | 7 labelers | n/a | Yes | No current entry | 0 |
| Carmustine | Gliadel | 10 labelers | n/a | Yes | No current entry | 0 |
| Lomustine | Gleostine | 1 labeler | n/a | Yes | No current entry | 0 |
| Busulfan | Myleran | 7 labelers | n/a | Yes | A presentation being discontinued | 1 |
| Ifosfamide | Ifex | 2 labelers | n/a | Yes | In shortage | 1 |
| Dacarbazine | none listed | 3 labelers | n/a | Yes | No current entry | 2 |
| Chlorambucil | Leukeran | none listed | n/a | Yes | No current entry | 0 |
| Trabectedin | Evdi, Yondelis | none listed | n/a | No | No current entry | 0 |
| Lurbinectedin | Zepzelca | none listed | n/a | No | No current entry | 0 |
| Mechlorethamine | Valchlor | none listed | n/a | No | No current entry | 0 |
| Procarbazine | Matulane | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price